FY2024 EPS Estimates for BioNTech Reduced by Leerink Partnrs

BioNTech SE (NASDAQ:BNTX) – Research analysts at Leerink Partnrs decreased their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a report issued on Wednesday, November 13th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnings of ($3.79) per share for the year, down from their previous estimate of ($1.84). The consensus estimate for BioNTech’s current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for BioNTech’s Q4 2024 earnings at $0.42 EPS, Q1 2025 earnings at ($1.81) EPS, Q2 2025 earnings at ($2.30) EPS, Q3 2025 earnings at $2.20 EPS, Q4 2025 earnings at $1.85 EPS, FY2025 earnings at ($0.07) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($2.04) EPS and FY2028 earnings at ($1.09) EPS.

A number of other analysts have also recently weighed in on the company. HSBC boosted their price target on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. TD Cowen lowered their price target on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a report on Tuesday, November 5th. UBS Group boosted their price objective on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 18th. Bank of America raised their target price on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Finally, Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $137.54.

BioNTech Trading Down 3.7 %

Shares of NASDAQ:BNTX opened at $99.72 on Monday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $23.91 billion, a PE ratio of -47.49 and a beta of 0.26. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The firm has a fifty day moving average price of $113.54 and a 200 day moving average price of $97.29.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.73 earnings per share.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BNTX. Covestor Ltd lifted its holdings in shares of BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after acquiring an additional 133 shares during the period. Planning Capital Management Corp raised its holdings in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after buying an additional 450 shares in the last quarter. Blue Trust Inc. lifted its position in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares during the period. EverSource Wealth Advisors LLC boosted its stake in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in BioNTech by 86.9% during the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after acquiring an additional 238 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.